Macrophages inhibit neovascularization in a murine model of age-related macular degeneration

PLoS Medicine

Volumn 3, Issue 8, 2006, Pages 1371-1381

  Apte, Rajendra S ^a   Richter, Jennifer ^a   Herndon, John ^a   Ferguson, Thomas A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; FAS LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PLAQUE FORMING CELL; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; AGING; ANIMAL; C57BL MOUSE; CELL DEATH; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; INJECTION; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; RETINA; TRANSGENIC MOUSE;

AGING; ANIMALS; CELL DEATH; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; INJECTIONS; INTERLEUKIN-10; MACROPHAGES; MACULAR DEGENERATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; RETINA;

EID: 33748353004     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030310     Document Type: Article

References (43)

1. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda SI, Kimura YN, et al. (2005) Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1beta-induced neovascularization and tumor growth. J Clin Invest 115: 2979-2991.
2. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, et al. (2005) Macrophage receptors and immune recognition. Annu Rev Immunol 23: 901-944.
3. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
4. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J (2003) Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3578-3585.
5. Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, et al. (2003) Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3586-3592.
6. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT (2003) Epidemiology of age-related maculopathy: A review. Eur J Epidemiol 18: 845-854.
7. Klein R, Peto T, Bird A, Vannewkirk MR (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 137: 486-495.
8. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60: 1119-1122.
9. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, et al. (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424.
10. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227-7232.
11. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421.
12. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
13. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, et al. (2003) An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med 9: 1390-1397.
14. Lobov IB, Rao S, Carroll TJ, Vallance JE, Ito M, et al. (2005) WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature 437: 417-421.
15. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 119: 198-207.
16. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
17. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA (1999) Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 5: 292-297.
18. Apte RS, Barreiro RA, Duh E, Volpert O, Ferguson TA (2004) Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest Ophthalmol Vis Sci 45: 4491-4497.
19. Miller JW, Walsh AW, Kramer M, Hasan T, Michaud N, et al. (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 113: 810-818.
20. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, et al. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114: 66-71.
21. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, et al. (2002) AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43: 1994-2000.
22. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, et al. (2006) Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum Gene Ther 17: 167-176.
23. Ferguson TA, Dube P, Griffith TS (1994) Regulation of contact hypersensitivity by interleukin 10. J Exp Med 179: 1597-1604.
24. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702.
25. Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, et al. (2000) Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A 97: 12758-12763.
26. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, et al. (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15: 837-846.
27. Verteporfin Roundtable 2000 and 2001 participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group principal investigators, Verteporfin in Photodynamic Therapy (VIP) Study Group principal investigators (2002) Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22: 6-18.
28. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
29. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62: 153-160.
30. Brown SB, Savill J (1999) Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 162: 480-485.
31. Diegelmann RF, Evans MC (2004) Wound healing: An overview of acute, fibrotic and delayed healing. Front Biosci 9: 283-289.
32. Park JE, Barbul A (2004) Understanding the role of immune regulation in wound healing. Am J Surg 187: 11S-16S.
33. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, et al. (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564-572.
34. VanNewkirk MR, Weih L, McCarty CA, Stanislavsky YL, Keeffe JE, et al. (2000) Visual impairment and eye diseases in elderly institutionalized Australians. Ophthalmology 107: 2203-2208.
35. Bonastre J, Le Pen C, Anderson P, Ganz A, Berto P, et al. (2002) The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 3: 94-102.
36. Miskala PH, Bressler NM, Meinert CL (2004) Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Arch Ophthalmol 122: 758-766.
37. Papadimitriou E, Antimisiaris SG (2000) Interactions of PC/Chol and PS/Chol liposomes with human cells in vitro. J Drug Target 8: 335-351.
38. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, et al. (2003) Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 105: 561-567.
39. Penfold PL, Madigan MC, Gillies MC, Provis JM (2001) Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20: 385-414.
40. Grossniklaus HE, Miskala PH, Green WR, Bressler SB, Hawkins BS, et al. (2005) Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: Submacular surgery trials report no. 7. Arch Ophthalmol 123: 914-921.
41. Grossniklaus HE, Wilson DJ, Bressler SB, Bressler NM, Toth CA, et al. (2006) Clinicopathologic studies of eyes that were obtained postmortem from four patients who were enrolled in the submacular surgery trials: SST report no. 16. Am J Ophthalmol 141: 93-104.
42. Kuo IC, Cunningham ET Jr (2000) Ocular neovascularization in patients with uveitis. Int Ophthalmol Clin 40: 111-126.
43. Gomez CR, Boehmer ED, Kovacs EJ (2005) The aging innate immune system. Curr Opin Immunol 17: 457-462.